Ultragenyx Reports Q1 Revenue Miss, Reaffirms Guidance, Advances Multiple Gene Therapy Programs

summarizeSummary

Ultragenyx Pharmaceutical reported first-quarter revenue of $136 million, falling short of analyst expectations, but reaffirmed its full-year financial guidance and provided positive updates on several key clinical programs, including two gene therapies with upcoming PDUFA dates.

check_boxKey Events

• Q1 2026 Financial Results

  Reported total revenue of $136 million, a net loss of $185 million, and $197 million in cash used from operations, with cash balance at $534 million as of March 31, 2026.

• Reaffirmed 2026 Financial Guidance

  Maintained full-year revenue guidance of $730 million to $760 million and reiterated the path to profitability in 2027, with combined R&D and SG&A expenses expected to be flat to slightly down versus 2025.

• Key Regulatory Milestones Achieved

  FDA accepted Biologics License Applications (BLAs) for DTX401 (GSDIa) with a PDUFA date of August 23, 2026, and for UX111 (MPS IIIA) with a PDUFA date of September 19, 2026.

• Positive Clinical Data for GTX-102

  New longer-term Phase 1/2 data for GTX-102 in Angelman syndrome showed durable and improving effects across multiple domains, with Phase 3 data expected in the second half of 2026.

auto_awesomeAnalysis

While Ultragenyx's first-quarter revenue of $136 million missed analyst estimates and the company reported a wider net loss and significant cash burn, the filing also highlights substantial progress across its clinical pipeline. The reaffirmation of full-year guidance and the path to profitability in 2027 provide some stability. Crucially, the company announced positive long-term data for GTX-102 in Angelman syndrome, and the FDA accepted BLAs for DTX401 (GSDIa) and UX111 (MPS IIIA) with PDUFA dates in August and September 2026, respectively. These regulatory milestones and clinical advancements are critical for a biopharmaceutical company and could serve as significant catalysts, potentially offsetting the near-term financial disappointments. Investors should monitor the upcoming PDUFA decisions and Phase 3 data readouts.